NASDAQ:QURE) business as it appears the company may be on the cusp of a considerable accomplishment. uniQure N.V., a gene therapy company, engages in the development and commercialization of treatments for patients suffering from genetic and other diseases in the Netherlands. The company’s loss has recently broadened since it announced a US$124.2m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$135.6m, moving it further away from breakeven. Many investors are wondering about the rate at which uniQure will turn a profit, with the big question being “when will the company breakeven?” Below we will provide a high-level summary of the industry analysts’ expectations for the company.” data-reactid=”28″>We feel now is a pretty good time to analyse uniQure N.V.’s (NASDAQ:QURE) business as it appears the company may be on the cusp of a considerable accomplishment. uniQure N.V., a gene therapy company, engages in the development and commercialization of treatments for patients suffering from genetic and other diseases in the Netherlands. The company’s loss has recently broadened since it announced a US$124.2m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$135.6m, moving it further away from breakeven. Many investors are wondering about the rate at which uniQure will turn a profit, with the big question being “when will the company breakeven?” Below we will provide a high-level summary of the industry analysts’ expectations for the company.
Check out our latest analysis for uniQure ” data-reactid=”29″> Check out our latest analysis for uniQure
According to the 14 industry analysts covering uniQure, the consensus is that breakeven is near. They anticipate the company to incur a final loss in 2019, before generating positive profits of US$60m in 2020. The company is therefore projected to breakeven around a year from now or less! How fast will the company have to grow to reach the consensus forecasts that anticipate breakeven by 2020? Working backwards from analyst estimates, it turns out that they expect the company to grow -27% year-on-year, on average,
Given this is a high-level overview, we won’t go into details of uniQure’s upcoming projects, but, keep in mind that by and large biotechs, depending on the stage of product development, have irregular periods of cash flow. This means that a low or volatile growth rate in the near future is not unusual, especially if the company is currently in an investment period.
One thing we’d like to point out is that The company has managed its capital prudently, with debt making up 13% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.
Next Steps:
uniQure’s company page on Simply Wall St. We’ve also put together a list of key aspects you should further examine:” data-reactid=”50″>There are too many aspects of uniQure to cover in one brief article, but the key fundamentals for the company can all be found in one place – uniQure’s company page on Simply Wall St. We’ve also put together a list of key aspects you should further examine:
- Valuation: What is uniQure worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether uniQure is currently mispriced by the market.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on uniQure’s board and the CEO’s background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
Get in touch with us directly. Alternatively, email [email protected].” data-reactid=”55″>This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected].
